Clinical trials: Amyloidosis Cardiac, open to volunteers
Light-chain Cardiac Amyloidosis
Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis
The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis.
- Trial name
- NCT07743957
- Testing
- XDd
- Volunteers
- 63 people
- Sponsor
- Beijing Anzhen Hospital
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Thailand ATTR-CM Registry
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally.
- Trial name
- NCT06338696
- Testing
- No intervention
- Where
- 8 sites in Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
The purpose of this study is to: Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed Demonstrate…
- Trial name
- TRITON-PN (NCT07223203)
- Testing
- Nucresiran, Vutrisiran
- Where
- 61 sites in United States, Argentina and 20 more
- Volunteers
- 125 people
- Sponsor
- Alnylam Pharmaceuticals
Transthyretin Cardiac Amyloidosis
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by amyloid fibril deposition, leading to heart failure and arrhythmias.
- Trial name
- FAPICAM (NCT07549841)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital
Cardiac Amyloidosis
Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags"
The study aims to test and compare the diagnostic yield of different diagnostic modalities (speckle tracking echocardiography, CMR, serum and urine protein analysis and bone tracer scintigraphy) in the detection of cardiac…
- Trial name
- NCT06175858
- Testing
- CMR
- Volunteers
- 30 people
- Sponsor
- Assiut University
Cardiac Amyloidosis, Pacemaker
Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis
In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more…
- Trial name
- PACE-ATTR (NCT07413081)
- Testing
- Increasing the pacemaker lower rate, Standard setting
- Where
- 9 sites in Denmark, Sweden
- Volunteers
- 34 people
- Sponsor
- Region Skane
Amyloidosis, AL Amyloidosis
BE.Amycon Biobank & Data Registry UZ Leuven
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database…
- Conditions
- Amyloidosis, AL Amyloidosis, Amyloidosis Cardiac
- Trial name
- NCT07172243
- Where
- 2 sites in Belgium
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cardiomyopathy, Ischemic Heart Disease
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV size and function, valvular disease severity) and…
- Conditions
- Cardiomyopathy, Ischemic Heart Disease, Cardiac Amyloidosis
- Trial name
- NCT07308704
- Testing
- Transthoracic Echocardiography (TTE)
- Where
- United States
- Volunteers
- 10,040,000 people
- Sponsor
- Mayo Clinic
Cardiac Amyloidosis
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid.
- Trial name
- PATHWAY-RCT (NCT05098665)
- Testing
- Telemonitoring service
- Where
- United Kingdom
- Volunteers
- 320 people
- Sponsor
- Richmond Research Institute
Coronary Arterial Disease (CAD), Plaque
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
ICECAP is a multi-centre, prospective, single-arm, interventional, traditional feasibility clinical investigation to evaluate the efficacy and safety of intra-coronary cryotherapy on vulnerable or high-risk plaque (HRP), using…
- Conditions
- Coronary Arterial Disease (CAD), Plaque, Vulnerable Plaque, Cryotherapy
- Trial name
- ICECAP (NCT06939374)
- Testing
- Intracoronary Cryotherapy
- Where
- 3 sites in Belgium, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cryotherapeutics SA
Cardiac Amyloidosis
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in elderly patients), leading to heart failure and arrhythmias.
- Trial name
- CATICA (NCT07648303)
- Testing
- Cardiac CT scan with contrast
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Systemic Amyloidosis, ATTR Amyloidosis
Hungarian National Systemic Amyloidosis Registry
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in inpatient and outpatient cardiology…
- Conditions
- Systemic Amyloidosis, ATTR Amyloidosis, AL Amyloidosis, Amyloid Cardiomyopathy
- Trial name
- AMYREG (NCT07689331)
- Where
- 12 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Transthyretin-type Cardiac Amyloidosis
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
- Trial name
- ATTR-CM (NCT07306949)
- Testing
- Acoramidis
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Trial name
- NCT06128629
- Testing
- NTLA-2001
- Where
- 138 sites in United States, Argentina and 24 more
- Volunteers
- 1,200 people
- Sponsor
- Intellia Therapeutics
Wild-type ATTR Amyloidosis, Amyloidosis Cardiac
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
This study explores whether extracellular vesicles (EVs) tiny particles released into the bloodstream by cells can serve as early and minimally invasive biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM).
- Conditions
- Wild-type ATTR Amyloidosis, Amyloidosis Cardiac, Amyloidosis, Hereditary, Amyloidosis Transthyretin
- Trial name
- EV-ATTR (NCT07314268)
- Where
- Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Transthyretin Cardiac Amyloidosis, Light Chain Cardiac Amyloidosis
[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis
This is a first in human study that will assess the safety, pharmacokinetics, biodistribution and diagnostic performance of [18F]FIDT-10b (fluorine-18 labeled FIDT-10b), a positron emission tomography (PET) agent.
- Trial name
- FIDTCA (NCT07835880)
- Testing
- [18F]FIDT-10b, 99mTc-PYP
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Cardiac Amyloidosis
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual…
- Trial name
- NCT05139797
- Testing
- EchoNet-LVH screening for cardiac amyloidosis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiac Amyloidosis
International Cardiac Amyloidosis Registry
Cardiac amyloidosis is a relatively rare disease. However, with the newer imaging techniques that have become available to us in recent years, determining the diagnosis is becoming more common. There are several variants.
- Trial name
- ICAR (NCT06894290)
- Where
- 6 sites in Belgium, Italy and 3 more
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
Amyloidosis, Amyloidosis Cardiac
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines…
- Conditions
- Amyloidosis, Amyloidosis Cardiac, ATTR Amyloidosis Wild Type
- Trial name
- NOTE-ATTR (NCT06251778)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Paolo Milani
Cardiac Amyloidosis
Registre HEAR, Healthcare European Amyloidosis Registry
This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed.
- Trial name
- NCT05101304
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Saving Lives Matters